Biophytis is a biotechnology business based in the US. Biophytis shares (BPTS) are listed on the NASDAQ and all prices are listed in US Dollars. Biophytis employs 26 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $1.09 |
|---|---|
| 52-week range | $0.94 - $10.99 |
| 50-day moving average | $1.41 |
| 200-day moving average | $4.25 |
| Wall St. target price | $15.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.78 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.09 from 2022-07-01
| 1 week (2022-06-24) | 0.93% |
|---|---|
| 1 month (2022-06-03) | -4.39% |
| 3 months (2022-04-01) | -50.00% |
| 6 months (2022-01-03) | -79.59% |
| 1 year (2021-07-02) | -88.85% |
|---|---|
| 2 years (2020-06-29) | N/A |
| 3 years (2019-06-29) | N/A |
| 5 years (2017-06-29) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -52.81% |
| Return on equity TTM | -783.82% |
| Profit margin | 0% |
| Book value | $0.42 |
| Market capitalisation | $18.5 million |
TTM: trailing 12 months
We're not expecting Biophytis to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Biophytis's shares have ranged in value from as little as $0.94 up to $10.99. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biophytis's is 1.4205. This would suggest that Biophytis's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
To put Biophytis's beta into context you can compare it against those of similar companies.
Biophytis S. A. , a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.